

Hypercholesterolemia Market to Evolve Rapidly with Emerging Therapies and Advancements by 2034, Forecasts DelveInsight

DelveInsight's Expert Market Assessment – A data-driven exploration of Hypercholesterolemia epidemiology and commercial potential across the 7MM.

LAS VEGAS , NV, UNITED STATES, February 3, 2025 /EINPresswire.com/ -- DelveInsight's "Hypercholesterolemia - Market Insight, Epidemiology, And Market Forecast - 2034" report offers an in-depth understanding of the Hypercholesterolemia, historical and forecasted epidemiology as well as the Hypercholesterolemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the Hypercholesterolemia market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [Hypercholesterolemia Market Forecast](#)

Some of the key facts of the Hypercholesterolemia Market Report:

- The total Hypercholesterolemia market size is estimated to grow with a significant CAGR during the study period (2024-2034).
- During the hypercholesterolemia analysis, it was found that around 31.7% of adults in the United States have high levels of LDL-C, putting them at twice the risk for heart disease compared to individuals with normal levels.
- The prevalence of hypercholesterolemia, specifically elevated LDL cholesterol levels, stood at 27.0%. This prevalence increases with age, reaching 48.4% among adults aged 65–74 years.
- In France, the prevalence of hypercholesterolemia was higher in men compared to women, with 29.7% of men affected.
- In Spain, the overall prevalence of hypercholesterolemia in the adult population was found to range between 34% and 50%.
- In October 2023, Verve Therapeutics announced that its investigational new drug (IND) application for VERVE-101, a gene-editing therapy intended to treat heterozygous familial hypercholesterolemia (HeFH), was cleared by the FDA.
- Emerging drugs include MK-0616, Lerodalcibep, and others.
- Key companies in the hypercholesterolemia treatment market include Aegerion Pharmaceutical, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, Sanofi, Amgen,

LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, and others.

Hypercholesterolemia Overview

Hypercholesterolemia is the abnormal accumulation of fluid in the abdomen, often causing discomfort, difficulty moving, and breathing. In severe cases, it can lead to infections, kidney failure, and hernias. Common in cirrhosis patients, Hypercholesterolemia occurs when liver function declines, raising pressure in liver veins (portal hypertension), which causes fluid buildup. It can also spread to the chest, affecting the lungs and making eating or drinking challenging.

Get a Free sample for the Hypercholesterolemia Market Report:

https://www.delveinsight.com/report-store/hypercholesterolemia-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr

Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypercholesterolemia Epidemiology Segmentation:

The Hypercholesterolemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total Prevalent cases of Hypercholesterolemia
- Gender-specific Prevalent Cases of Hypercholesterolemia
- Age-specific Prevalent Cases of Hypercholesterolemia
- Diagnosed and Treatable cases of Hypercholesterolemia

Download the report to understand which factors are driving Hypercholesterolemia epidemiology trends @ [Hypercholesterolemia Epidemiology Forecast](#)

Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypercholesterolemia market or expected to be launched during the study period. The analysis covers Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypercholesterolemia Pipeline Development Activities. It provides

valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypercholesterolemia Therapies and Key Companies

- Enlicitide Decanoate - Merck Sharp & Dohme
- Lerodalcibep - LIB Therapeutics

Hypercholesterolemia Market Strengths

- The market is supported by the extensive use of statins, along with newer therapies such as PCSK9 inhibitors (e.g., evolocumab, alirocumab), which effectively lower LDL cholesterol and reduce cardiovascular risk.
- A promising pipeline of new drugs, including combination therapies and gene therapies, aims to offer better efficacy, longer-lasting results, and fewer side effects, improving treatment outcomes for patients.

Hypercholesterolemia Market Opportunities

- As the global incidence of cardiovascular diseases rises, driven by lifestyle factors and an aging population, the demand for effective hypercholesterolemia treatments is expected to increase significantly.
- Despite the availability of treatments, a substantial portion of patients with hypercholesterolemia remains under-treated, especially those with familial hypercholesterolemia or high cardiovascular risk, creating opportunities for novel, personalized therapies.

Scope of the Hypercholesterolemia Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hypercholesterolemia Companies: Aegerion Pharmaceutical, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, Sanofi, Amgen, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, and others.
- Key Hypercholesterolemia Therapies: MK-0616, Lerodalcibep, and others.
- Hypercholesterolemia Therapeutic Assessment: Hypercholesterolemia current marketed and Hypercholesterolemia emerging therapies
- Hypercholesterolemia Market Dynamics: Hypercholesterolemia market drivers and Hypercholesterolemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Hypercholesterolemia Market Access and Reimbursement

To learn more about Hypercholesterolemia companies working in the treatment market, visit @

[Hypercholesterolemia Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Hypercholesterolemia Market Report Introduction
2. Executive Summary for Hypercholesterolemia
3. SWOT analysis of Hypercholesterolemia
4. Hypercholesterolemia Patient Share (%) Overview at a Glance
5. Hypercholesterolemia Market Overview at a Glance
6. Hypercholesterolemia Disease Background and Overview
7. Hypercholesterolemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypercholesterolemia
9. Hypercholesterolemia Current Treatment and Medical Practices
10. Hypercholesterolemia Unmet Needs
11. Hypercholesterolemia Emerging Therapies
12. Hypercholesterolemia Market Outlook
13. Country-Wise Hypercholesterolemia Market Analysis (2020–2034)
14. Hypercholesterolemia Market Access and Reimbursement of Therapies
15. Hypercholesterolemia Market Drivers
16. Hypercholesterolemia Market Barriers
17. Hypercholesterolemia Appendix
18. Hypercholesterolemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/782772930>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.